肿瘤预防与治疗2017，Vol.30Issue(4)：313-318,6.DOI:10.3969/j.issn.1674-0904.2017.04.014
CD44+/MyD88+卵巢癌转移、耐药及预后的研究进展
Research Progress in Metastasis, Drug Resistance and Prognosis of CD44 +/MyD88 + Ovarian Cancer
张宏涛 1朱熠2
作者信息
- 1. 646000 四川 泸州,西南医科大学附属医院 肿瘤科
- 2. 610041 成都,四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学医学院 超声中心
- 折叠
摘要
Abstract
Ovarian cancer is one of the three major malignant tumors of gynaecology oncology,and the motality of which comes first among gynecologic malignant tumors.Chemotherapy drugs selectively combined with ovarian cancer cells based on specificity of molecules marker on the surface of cancer cells can effectively eliminate the recurrence and drug resistance of cancer.Targeted therapy has become a focus of studying.Researches show that MyD88 and CD44 are expressed in ovarian cancer and play an important role in the development,invasion,metastasis,and drug-resistance of ovarian cancer.The major emphasis of this article is to review the latest researches on the metastasis,drug-resistance and prognosis related with the CD44 +/MyD88 + ovarian cancer.关键词
卵巢癌/CD44/MyD88/耐药Key words
Ovarian cancer/CD44/MyD88/Drug-resistance分类
医药卫生引用本文复制引用
张宏涛,朱熠..CD44+/MyD88+卵巢癌转移、耐药及预后的研究进展[J].肿瘤预防与治疗,2017,30(4):313-318,6.
